Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

p a roadmap to approval.

The regulatory filing in the European Union is ongoing. Arpida has received an intermediate report from the European Medicines Agency (EMEA) containing the findings of the review carried out so far. The company is working closely with EMEA to address the topics it has put forward.

The Canadian filing is currently not being pursued.

Oral iclaprim in cSSSI - in-depth analysis ongoing for further design of development plan

In December 2008, Arpida announced the top-line results of a Phase II "intravenous-to-oral" switch trial with iclaprim in patients with cSSSI. In parallel with the Phase II trial, the last ongoing study of the Phase I programme has been closed.

Based on the review to date, Arpida expects that further development work will be required in order to better understand the effect of orally administrated iclaprim on liver enzymes and to explore optimal dosing regimens.

Other programmes:

In December 2008, a re-alignment of activities was initiated. The action plan to reduce costs impacts the development programmes in different ways:

    - study stopped: Phase II with intravenous iclaprim in HAP/VAP/HCAP
    - late preclinical studies stopped: AR-709 and AR-2474
    - trial ongoing, further patient enrolment stopped: Phase III study with
      TLT in onychomycosis.

A PDF-file containing the preliminary 2008 annual report (in English) is available on our website (http://www.arpida.com) starting 25 February 2009, noon.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the
'/>"/>

SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Memphis, TENN (PRWEB) December 22, 2014 ... with Donor Egg Bank USA , a network ... the country. Through this partnership, patients have fast access ... for in vitro fertilization, IVF . Fertility Associates of ... to offer this fertility treatment option. , Dr. ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that its ... M1 in raw commingled milk is the first lateral ... peer reviewed report of the validation by Technology and ... Fisheries Research (ILVO-T&V) has been published by the Taylor ... toxic aflatoxin and a known carcinogen, can be passed ...
(Date:12/19/2014)... 19, 2014 Naurex Inc., a biopharmaceutical company ... diseases of the central nervous system, today announced that ... officer, will present at the 33 rd annual ... place at 3:00 p.m. PST on Tuesday, January 13, ... San Francisco, Calif. About ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... for functional food partners and market entrance, ... Neptune Technologies &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT - ... has been determined to be,safe as a ... for the,commercialization of NKO(R) incorporated into different ...
... after biological olfaction, the challenge has been to generate ... complexity to detect odors in the real world. A ... with exact chemical precision and reproducibility. , In a ... PLoS Biology, Joel White, Mary AtKisson, John Kauer and ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... discussing its,financial results for the fourth quarter and year ended December ... 2008 at 11:00 AM ET (8:00 ... Dial information is as follows: ...
Cached Biology Technology:Neptune Technologies receives GRAS notification in the United States 2Neptune Technologies receives GRAS notification in the United States 3Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast 2
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ... expand its team and bring LaunchKey to market in ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... sodium-retaining hormone in African Americans known to potentially cause ... of a study in the September issue of Experimental ... Temple Universitys College of Health Professions. The hormone, ... too much of it can contribute to the development ...
... may hold vital clues about how pancreatic cancer and diabetes ... access journal BMC Medicine, women with a history of gestational ... in life. The research team drawn from the US ... 37,000 mothers who gave birth between 1964 and 1976 in ...
... for our new disease problems, a far more cost ... in the places where they often commingle: in wildlife ... from the Wildlife Conservation Society (WCS) and the United ... issue of the prestigious Journal of Wildlife Diseases. ...
Cached Biology News:Understanding hypertension in African Americans proves elusive 2Emerging (disease) markets 2
...
Request Info...
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
Biology Products: